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CLINICAL AND POPULATION STUDIES
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OBJECTIVE: Characterize homozygous familial hypercholesterolemia (HoFH) individuals from Iberoamerica.
APPROACH AND RESULTS: In a cross-sectional retrospective evaluation 134 individuals with a HoFH phenotype, 71 adults (age 
39.3±15.8 years, 38.0% males), and 63 children (age 8.8±4.0 years, 50.8% males) were studied. Genetic characterization 
was available in 129 (96%). The majority (91%) were true homozygotes (true HoFH, n=79, 43.0% children, 46.8% males) or 
compound heterozygotes (compound heterozygous familial hypercholesterolemia, n=39, 51.3% children, 46.2% males) with 
putative pathogenic variants in the LDLR. True HoFH due to LDLR variants had higher total (P=0.015) and LDL (low-density 
lipoprotein)-cholesterol (P=0.008) compared with compound heterozygous familial hypercholesterolemia. Children with true 
HoFH (n=34) tended to be diagnosed earlier (P=0.051) and had a greater frequency of xanthomas (P=0.016) than those 
with compound heterozygous familial hypercholesterolemia (n=20). Previous major cardiovascular events were present in 25 
(48%) of 52 children (missing information in 2 cases), and in 43 (67%) of 64 adults with LDLR variants. Children who are 
true HoFH had higher frequency of major cardiovascular events (P=0.02), coronary heart (P=0.013), and aortic/supra-aortic 
valve diseases (P=0.022) than compound heterozygous familial hypercholesterolemia. In adults, no differences were observed 
in major cardiovascular events according to type of LDLR variant. From 118 subjects with LDLR variants, 76 (64%) had 2 
likely pathogenic or pathogenic variants. In 89 subjects with 2 LDLR variants, those with at least one null allele were younger 
(P=0.003) and had a greater frequency of major cardiovascular events (P=0.038) occurring at an earlier age (P=0.001).
CONCLUSIONS: There was a high frequency of cardiovascular disease even in children. Phenotype and cardiovascular 
complications were heterogeneous and associated with the type of molecular defect.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
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Homozygous familial hypercholesterolemia (HoFH) is a rare disorder, affecting 1 in 300 000 to 1 000 000 people in the general population.1,2 In >90% of 
cases, FH is caused by variants in both alleles of the 
LDL (low-density lipoprotein)-receptor gene (LDLR). 
Other less frequent affected genes are APOB, propro-
tein convertase subtilisin/kexin type 9 (PCSK9), or LDL-
RAP1.1 Clinically, it is characterized by extremely high 
LDL-C (LDL-cholesterol) levels, in general, >500 mg/dL 
or >300 mg/dL under standard lipid-lowering treatment 
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(statins, ezetimibe, bile acid bind resins, and niacin), cuta-
neous xanthomas of early appearance, abnormalities of 
aortic valve and supravalvar region of aortic root, and 
multivessel atherosclerotic cardiovascular disease.3–5 
Usually, if affected individuals are not treated, they may 
not survive beyond the third decade of life.6,7 However, 
recent evidence suggests that HoFH present a more 
heterogenous phenotype than previously thought, and 
this has been ascribed to the severity of the molecular 
defects that cause the disease.2,8–10
The Iberoamerican community has an estimated pop-
ulation of 640 million individuals. The Iberoamerican FH 
network was constituted in 2013, with the main objec-
tives of promoting awareness and education on FH and 
improving early diagnosis and treatment of the disorder 
in the network countries. Currently, there are 8 countries 
(Argentina, Brazil, Chile, Colombia, Mexico, Portugal, 
Spain, and Uruguay) belonging to the network represent-
ing 75% of the region’s population. It is estimated that 
there are between 600 and 1,800 HoFH in Iberoamer-
ica, most of them undiagnosed or not treated adequately. 
In most countries, treatment of HoFH has been limited 
to the use of statins and ezetimibe, treatments that have 
been shown to modestly reduce LDL-C levels. Unfortu-
nately, LDL-apheresis, the current gold standard treat-
ment for HoFH, is not available in most countries of the 
region.
With the exception of Spain, there is very little informa-
tion about clinical and molecular characteristics of HoFH 
individuals in Iberoamerica.10–13 Recently, molecular and 
clinical characteristics of FH from countries belonging 
to the Iberoamerican FH network have been described.14 
The objective of this study is to expand this to the identi-
fied HoFH adults and children in Iberoamerica, as well as 
to describe the association of the genetic variant types 
with phenotypic expression of the disorder.
MATERIALS AND METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Study Population
This is a cross-sectional, retrospective study that describes 
clinical, laboratory, and molecular characteristics of identified 
adults and children (<18 years old) with HoFH from centers 
belonging to the Iberoamerican FH network. The inclusion 
criteria for the study were (1) a positive molecular diagnosis 
in individuals with a compatible HoFH phenotype; (2) in the 
absence of molecular testing, a phenotype compatible with 
HoFH according to international statements.3,4 The majority 
of cases reported in this study underwent genetic testing in 
specialized molecular laboratories in Argentina, Brazil, Mexico, 
Portugal, Spain, and Uruguay. Subjects with HoFH due to LDLR, 
APOB, or PCSK9 variants and those with autosomal recessive 
hypercholesterolemia (LDLRAP1 gene) were included either if 
they were true (true HoFH [THoFH]) homozygotes, compound 
heterozygotes (compound heterozygous FH [CHeFH]), or dou-
ble heterozygotes. Only individuals with 2 putative variants in 
trans were accepted for this study; subjects with synonymous 
or putative splicing point substitutions variants outside the ±1 
to 6 region were excluded.
Clinical Data and Laboratory Assessments
Clinical and laboratory data at diagnosis and follow-up when 
available were obtained from patient medical files or con-
tacting physicians responsible for patient care and included: 
demographics (age at diagnosis and follow-up, sex, and living 
status), history of cardiovascular disease, physical examina-
tion (xanthomas and corneal arcus), and type of lipid-lowering 
treatment (including LDL-apheresis) used. Total cholesterol at 
screening, untreated or highest on treatment (available for all 
subjects), or complete lipid profile (available for 101 subjects, 
75%) were considered for the diagnosis. Lipid profile was also 
assessed during follow-up if available. LDL-C was calculated 
by Friedewald equation if triglyceride levels were <400 mg/dL 
in all centers. Lp(a) (lipoprotein[a]) values (mg/dL) when avail-
able were also collected.
Major adverse cardiovascular events (MACE) at the moment 
of inclusion were defined as any clinical manifestation of coronary 
Nonstandard Abbreviations and Acronyms
CHD coronary heart disease
CHeFH  compound heterozygous familial 
hypercholesterolemia
FH familial hypercholesterolemia
HoFH  homozygous familial 
hypercholesterolemia
LDL low-density lipoprotein
LDL-C low-density lipoprotein cholesterol
LDLR LDL receptor
MACE major adverse cardiovascular events
PCSK9  proprotein convertase subtilisin/kexin 
type 9
THoFH  true homozygous familial 
hypercholesterolemia
VUS variant of unknown significance
Highlights
• Clinical and molecular data from a large number of 
adults and children with HoFH from Iberoamerica 
are reported.
• Phenotypic expression is highly variable according 
to the molecular defect.
• True homozygous FH children had higher frequency 
of MACE than compound heterozygous FH children.
• Subjects with at least one null allele variant had a 
greater frequency of MACE, occurring at an early 
age compared with those with defective variants.
• Hypercholesterolemia due to HoFH in Iberoamerica 
is highly uncontrolled.
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heart disease (CHD; myocardial infarction, angina pectoris, surgi-
cal or percutaneous coronary revascularization); atherothrombotic 
stroke; carotid artery disease defined as obstructive plaques > 
50% on doppler ultrasound; peripheral artery disease (claudication, 
amputation or limb revascularization); and presence of aortic or 
supra-aortic valve disease defined as presence of heart murmurs 
either of stenosis or regurgitation in the aortic auscultation area 
confirmed by Doppler ultrasound or previous valve replacement.
Molecular Analysis
DNA analysis was performed in different laboratories as pre-
viously described.15–19 References used for LDLR, APOB, 
PCSK9, LDLRAP1 genes were NM_000527.4, NM_000384.2, 
NM_174936.3, and NM_015627.2, respectively. cDNA num-
bering was considered with nucleotide c.1 being the A of the 
ATG initiation codon p.1.20 All variants were annotated and 
checked using Mutalyzer v2.0 and converted to the nomencla-
ture recommended by the Human Genome Variation Society.
In Silico Classification
In silico analysis was performed for every variant using open-
access software and included the following programs: Protein 
Variation Effect Analyzer Sorting Tolerant From Intolerant, 
PolyPhen-2, and Mutation Taster for prediction of protein struc-
ture/function changes and evolutionary conservation; Neural 
Network Splice Site Prediction Tool, MAXENTSCAN, FSPLICE, 
and Human splicing finder for prediction of splicing defects, as 
previously described.21
Variant Classification
Variant classification was performed according to the American 
College of Medical Genetics and Genomics 2015 guideline22 as 
pathogenic, likely pathogenic, variant of unknown significance 
(VUS), likely benign and benign, with FH specifications described 
in Chora et al.21 Only individuals with pathogenic, likely pathogenic 
and VUS were included in the genetic characterization study.
Allele Classification
All nonsense, large deletions, frameshift variants, and all vari-
ants that have been proven by in vitro functional assays that 
lead to <2% LDLR activity were considered to be null variants. 
All other variants were classified as defective. For all cases 
where no functional assays were performed, an estimated (*) 
allele classification was given (null* or defective*), according 
to the predicted functional effects of the variants considering 
their type (structural and functional) and in silico analysis (3 
concordant programs). Variants where the in silico programs 
mentioned above were not possible to be performed (as for in-
frame deletions-insertions) or variants that did not have a con-
cordant in silico classification in at least 3 programs could not 
be classified concerning their allele type. Also, variants where a 
prediction of null or defective alleles could not be made, as for 
splicing variants without transcript quantification, classification 
according to allele type was also not performed. Subjects with 
variants fulfilling the 2 latter situations were not included for 
allele type-based analysis. In CHeFH cases in which at least 
one of the variants was considered as null (or null*), the case 
was included in the null category for data analysis.
Statistical Analysis
Continuous data are expressed as means±SD, except for 
Lp(a) that was expressed as medians (%25; %75). Categorical 
data are expressed as frequency (%). Subjects were ana-
lyzed according to their gene variants, lipid profile (highest 
values available), risk factors for cardiovascular disease, as 
well as presence of MACE and type of lipid-lowering medica-
tion. Statistical analysis was performed using SPSS software 
(version 25.0 for Windows; SPSS, Chicago, IL). Comparison 
of frequencies between qualitative variables was carried out 
using the χ2 or Fisher exact tests. Mean values of quantitative 
variables were compared with the Student t test or ANOVA 
for independent data, whereas median values were compared 
with the nonparametric median tests Mann-Whitney or Kruskal-
Wallis. A P<0.05 was considered statistically significant. To 
reduce uncertainty, P values were considered as nominal when 
data from all participants were not available for analysis.
Ethics
Local ethics committees approved each country study, and eli-
gible subjects, or legal representatives in the case of children 
and teenagers, gave written informed consent for study partici-
pation. Data analysis was totally anonymized.
RESULTS
The study population consisted of 134 individuals with 
a HoFH phenotype: 71 adults (mean age, 39.3±15.8 
years, 38.0% males) and 63 children (mean age 
8.8±4.0 years, 50.8% males). Molecular testing was 
available for 129 out of 134 subjects (96%). The great 
majority (91%) were THoFH (n=79, 43.0 % children 
[n=34], 46.8% males) or CHeFH (n=39, 51.3% chil-
dren [n=20], 46.2% males) with variants in the LDLR 
gene (Figure I in the Data Supplement). Only one true 
homozygote for APOB variant was found in Chile. 
No THoFH for gain of function PCSK9 variants were 
encountered in the region, but a compound heterozy-
gote for PCSK9 had been described in Portugal.23 Five 
THoFH for LDLRAP1 variants were encountered: 1 in 
Brazil, 1 in Colombia, and 3 in Spain. Table I in the Data 
Supplement shows the distribution of subjects accord-
ing to country of origin and genotype.
Table 1 shows subjects’ lipid profile at diagnosis (base-
line values or highest on treatment) according to geno-
type with total cholesterol values for the whole cohort 
(n=134) and a complete lipid profile for 101 (75%) 
subjects. Of importance, 17% (n=23) of study subjects 
were not in use of lipid-lowering treatment at screening. 
THoFH due to LDLR variants had higher total choles-
terol (P=0.015) and LDL-C (P=0.008) as well as lower 
HDL-C (high-density lipoprotein cholesterol; P=0.012) 
compared with CHeFH. No differences in total choles-
terol and LDL-C were found when compared THoFH to 
LDLRAP1 subjects, although the latter tended to have 
higher LDL-C than CHeFH. However, these analyses 
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were compromised by the small number of subjects on 
the LDLRAP1 group.
Table 2 shows clinical and laboratory characteristics 
of children (n=54) and adults (n=64) with THoFH or 
CHeFH due to LDLR variants (n=118). THoFH chil-
dren (n=34) tended to be diagnosed at a younger age 
(P=0.051) and had a greater frequency of xanthomas 
(P=0.016) than those with CHeFH (n=20). Previous 
MACE was present in 25 (48%) of 52 children, with 
missing information in 2 cases. Mean age for the first 
MACE was 11 years. Children who are THoFH had 
higher occurrence of MACE (P=0.02), CHD (P=0.013), 
and aortic valve disease (P=0.022) than children with 
CHeFH. In Table II in the Data Supplement clinical and 
laboratory characteristics of all children according to clin-
ical (n=4) and molecular diagnoses (n=59) are shown.
However, in adults, MACE was present in 43 (67%) 
out of 64 individuals with LDLR variants, and no sig-
nificant differences were observed in each individual 
component of MACE between true or compound het-
erozygotes. However, differently from children, the most 
frequent clinical manifestation in adults was CHD in 
either THoFH or CHeFH.
Regarding plasma lipids, a complete lipid profile 
was available for 28 (84%) THoFH and 16 (80%) 
CHeFH children (Table 2). True homozygous had higher 
total (P=0.023), LDL-C (P=0.018), and lower HDL-C 
(P=0.026) than CHeFH children. In adults, a complete 
lipid profile was available in 28 (62%) THoFH and 14 
(74%) CHeFH, and only LDL-C was significantly higher 
in THoFH (P=0.045). Lp(a) was available in 17 chil-
dren and 27 adults and no differences were observed 
between THoFH and CHeFH: children 26 (5; 52) mg/
dL versus 29 (16; 82) mg/dL, (nominal P=0.841) and in 
adults 31 (10; 65) mg/dL versus 34 (19; 121) mg/dL 
(nominal P=0.581).
Children with THoFH had a significantly higher fre-
quency of at least one null allele than those with CHeFH 
(P=0.016). In children with aortic/supra-aortic valve 
disease, 75% had LDLR null variants, compared with 
only 25% of the adults. All children developed aortic/
supra-aortic valve disease before CHD manifestations. In 
adults, the frequency of null/null individuals was signifi-
cantly higher in THoFH (P=0.035).
A total of 45 different LDLR variants were found in 
THoFH and are described in Table III in the Data Sup-
plement as well as the LDL-C levels presented by their 
carriers, when available. Twenty-three THoFH subjects 
are carriers of 12 VUS variants. Due to the classical 
HoFH phenotype, LDL-C >500 mg/dL, or LDL-C >300 
mg/dL on treatment, presented by their carriers, at least 
6 could be considered disease causing (highlighted in 
Table III in the Data Supplement). However, functional 
studies will be necessary to assess all these variants to 
establish their pathogenicity.
From 118 subjects with LDLR variants, 76 (64%) had 
2 likely pathogenic or pathogenic variants. The remain-
ing 42 subjects carried at least one VUS meaning that 
there was not enough evidence for these variants to be 
considered at least likely pathogenic according to the 
American College of Medical Genetics and Genomics 
classification.21,22
Table IV in the Data Supplement shows clinical and 
laboratory data for 89 subjects with 2 LDLR variants in 
which it was possible to classify these as null or defective 
alleles. Those with at least one null allele were diagnosed 
at a younger age (P=0.032), had a greater frequency 
of MACE (P=0.038), especially aortic/supra-aortic valve 
disease (P=0.026), occurring at an earlier age (P=0.001), 
and a trend to higher frequency of xanthomas (P=0.051) 
than those subjects with defective variants. Also, those 
with null variants tended to have a greater mortality 
Table 1. Complete Lipid Profile According to Genotype (n=101) and TC for the Whole Cohort (n=134) of Patients With HoFH
n* TC* LDL-C* HDL-C* TG* TC†
LDLR true 56/79 692±182 628±181 38±12 128±48 656±224
LDLR compound 30/39 589±147 518±149 45±14 131±80 569±142
LDLRAP1 true 4/5 715±155 649±141 40±7 129±44 648±201
APOB true 1/1 405 330 36 183 405
PCSK9 compound 1/1 305‡ 220‡ 50‡ 58‡ 305
LDLR+APOB double 3/3 570±108 487±99 51±14 160±58 570±108
LDLR+PCSK9 double 1/1 454 325 73 390 454
Without genetic test 5/5 626±196 546±192 34±10 208±81 626±196
P value; LDLR true vs LDLR compound  0.015 0.008 0.012 0.520 0.039
P value; LDLR true vs LDLRAP1  0.658 0.568 0.577 0.830 0.987
P value; LDLR compound vs LDLRAP1  0.117 0.064 0.738 0.699 0.329
At screening 17% of study subjects were not receiving lipid-lowering treatment. TC, LDL-C, HDL-C, and TG in mg/dL. HDL-C indicates high-density lipoprotein cho-
lesterol; HoFH, homozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; and TG, triglycerides.
*Baseline or highest on-treatment values at screening for complete lipid profile (available for 101 subjects).
†Baseline or highest on treatment for total cholesterol values at screening for all 134 homozygous FH patients.
‡On-treatment values were considered for diagnosis.
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frequency (P=0.062). The baseline untreated or highest 
on-treatment values of lipid profiles were available for 63 
studied subjects (71%) and showed higher concentra-
tions of total cholesterol (P=0.035), LDL-C (P=0.024), 
and lower HDL-C (P=0.005) in those presenting at least 
one null variant. No differences in Lp(a) values were 
observed between these 2 groups 31 (22; 57) mg/dL 
and 29 (9; 47) mg/dL), nominal P=0.131, respectively, 
for null (n=16) and defective (n=19).
Figure II in the Data Supplement shows that THoFH 
and CHeFH children with either null or defective alleles 
had higher LDL-C compared with adults (679±170 mg/
dL versus 561±97 mg/dL, both null alleles; P=0.03, and 
654±136 mg/dL versus 503±153 mg/dL, both defec-
tive, P=0.03). This in part may be related to the fact that 
22% of the children were untreated at the time of clinical 
diagnosis when compared with 10.9% of adults.
There was a marked difference among countries 
concerning available lipid-lowering treatments (Table V 
in the Data Supplement), and this was reflected in the 
frequency of use of different therapies. Most patients 
(70%) were using statins in monotherapy or combined 
with ezetimibe. However, there was a greater use of 
either PCSK9 inhibitors or the microsomal triglyceride 
transfer protein inhibitor, lomitapide, in those with null 
variants than in those with defective ones (28.3% versus 
5.6% P=0.012) in countries where these medications 
were available. Overall, there were very low rates of LDL-
apheresis (n=11, 8.2% of all studied subjects). All sub-
jects on combined therapy with PCSK9 inhibitors (n=7), 
lomitapide (n=10), on LDL-apheresis (n=11), or that 
Table 2. Clinical and Laboratory Characteristics of 118 HoFH Children and Adults With Identified LDLR Variants
Children (n=54) Adults (n=64)
THoFH (n=34) CHeFH (n=20) P Value THoFH (n=45) CHeFH (n=19) P Value
Age at diagnosis, y 7.9±4.0 10.1±4.0 0.051 37.8±16.5 43.7±13.2 0.140
Age at inclusion, y 12.9±6.7 13.3±5.1 0.424 45.6±17.8 49.6±13.7 0.410
Male sex, n (%) 15 (55.9%) 11 (55.0%) 0.999 18 (40.0%) 7 (36.8%) 0.999
Living status (dead), n (%) 5 (14.7%) 2 (10.0%) 0.999* 5 (11.2%) 0 (0%) 0.309*
Xanthomas, n (%) 31 (91.2%) 12 (60.0%) 0.016 27 (60.0%) 12 (63.2%) 0.267
Corneal arcus, n (%) 15 (48.4%) 6 (30.0%) 0.377 28 (62.2%) 9 (47.4%) 0.408
Hypertension, n (%) 0 (0%) 0 (0%) … 13/33 (39.4%) 3/13 (23.1%) 0.070*
Diabetes mellitus, n (%) 0 (0%) 0 (0%) … 3/33 (9.1%) 0/13 (0%) 0.001*
Current smokers, n (%) 0 (0%) 0 (0%) … 2/33 (6.1%) 2/13 (15.4%) 0.001*
Allele type
 Null/Null 13 (38.2%) 6 (30.0%) 0.108 9 (20.0%) 2 (10.5%) 0.035
 At least one Null 21 (61.7%) 8 (40.0%) 0.016 16 (35.6%) 9 (47.4%) 0.162
 Defective/Defective 6 (17.6%) 6 (30.0%) 0.045 20 (44.4%) 4 (21.1 %) 0.001
Cardiovascular disease
 MACE, n (%) 19/33 (55.9%) 6/19 (31.6%) 0.040* 29/45 (45.3%) 14/19 (73.7%) 0.007
  CHD, n (%) 5/28 (17.9%) 1/19 (8.3%) 0.001* 23/43 (53.5%) 12/19 (63.2%) 0.583*
  Stroke, n (%) 0/19 0/12 … 0/45 (0%) 1/19 (5.3%) 0.227
  PVD, n (%) 1/19 (5.3%) 1/12 (8.3%) 0.005* 1/40 (2.5%) 0/19 (0%) 0.688*
  Aortic/supra aortic valve disease, n (%) 13/31 (41.9%) 4/17 (23.5%) 0.009* 4/43 (9.3%) 1/17 (5.9%) 0.267*
 Age first event, y (n) 11.1±4.6 11.0±2.0 0.947* 30.3±15.6 38.0±12.7 0.440
Lipid levels
 TC, mg/dL† 767±178 645±149 0.014 630±202 541±122 0.024
 Lipid profile‡ N=28/34 N=16/20 … N=28/45 N=14/19 …
 TC, mg/dL 753±171 636±150 0.023* 630±173 536±127 0.088*
 LDL-C, mg/dL 691±170 568±146 0.018* 564±171 461±135 0.045*
 HDL-C, mg/dL 37±14 45±16 0.026* 39±11 44±12 0.189*
 TG, mg/dL 122±37 109±50 0.184* 133±57 155±102 0.626*
Only subjects with complete lipid profile are included in the analysis, 81.5% of the children and 65.6% of the adults. CHD indicates coronary heart disease; CheFH, 
compound heterozygous familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; HoFH, homozygous familial hypercholesterolemia; LDL-C, low-
density lipoprotein cholesterol; MACE, major cardiovascular events; PVD, peripheral vascular disease; TC, total cholesterol; TG, triglycerides; and THoFH, true HoFH
*Nominal P values when data not available for all study subjects.
†Baseline or highest on treatment for total cholesterol values at screening for 118 homozygous FH patients.
‡Baseline or highest on-treatment lipid levels from the same sample.
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were submitted to liver transplantation (n=7) had LDL-C 
reductions over 50%, the minimum recommended target 
to treat these individuals2,4 (data not shown).
DISCUSSION
In this study, clinical and molecular data from a large 
number of adults and especially children with HoFH 
from Iberoamerica are reported. Molecular diagnosis 
was performed in 96% of studied subjects; therefore, 
it was possible to show genotype/phenotype associa-
tions. The main findings of this study are (1) that most 
HoFH in Iberoamerica are caused by LDLR defects; 
(2) this population is characterized by high frequency 
of early-onset MACE, even in children; (3) phenotype 
and cardiovascular complications are heterogeneous 
and associated with the type of molecular defect, and 
those bearing a null LDLR variant had a more severe 
phenotype; and (4) cholesterol levels are mostly 
uncontrolled and not on target independently of the 
encountered genotype.
As previously described mostly in European and North 
American populations,9,10,24–26 the comparison of clini-
cal and biochemical data by allele type and distribution 
showed significant differences in plasma lipids between 
studied groups. Both THoFH children and adults showed 
more severe hypercholesterolemia than their CHeFH 
counterparts. In children, almost 40% of studied individu-
als in which information was available presented some 
manifestation of cardiovascular disease, mostly aortic/
supra-aortic valve disease, and there was a higher fre-
quency of MACE in the THoFH individuals. However, 
because the latter may carry 2 defective alleles, whereas 
subjects that are CHeFH can bear 2 null alleles, the 
comparison between true and compound HoFH indi-
viduals may not reflect the phenotypic differences and 
consequent cardiovascular complications. Indeed, sub-
jects with null alleles are expected to have a more severe 
phenotype than subjects with defective allele variants 
because the former will have virtually no functional LDL 
receptors on hepatocytes.10,25,27 However, subjects with 
2 defective allele variants will have some residual LDL 
receptor activity, a higher plasma LDL clearance, and 
therefore, cardiovascular disorders may show up later in 
life. Indeed, in this study, those presenting at least one 
null allele were diagnosed earlier, had a more severe lipid 
profile, a greater frequency, and earlier MACE, and pos-
sibly early death onset than those with defective alleles. 
This was apparent when children were compared with 
adults, the lower frequency of null variants in the latter 
probably indicates a survival bias especially when the fre-
quency of aortic/supra-aortic valve disease is concerned. 
Of course, a greater time exposure to high LDL-C in 
adults certainly is responsible for the greater frequencies 
of CHD when compared with children.
The information gathered on THoFH subjects can be 
useful to classify the variants carried by these subjects. 
If a patient is a true homozygote for a certain variant 
and presents a severe phenotype (untreated LDL-C 
>500 mg/dL or LDL-C >300 mg/dL on treatment), 
the variant found must be the one causing disease if 
it produces such a severe phenotype; however, func-
tional assays should always be performed to confirm 
pathogenicity because there is the rare chance that 
the patient could have another undetected variant that 
defines the phenotype.28
From the list of 45 variants found in true homozygous 
subjects, 12 are VUS but 6 were found in subjects with 
a classical HoFH phenotype. These variants are likely 
to be causal and, therefore, pathogenic. However, there 
are 3 variants shown in homozygosity p.(Arg300Gly), 
p.(Ser326Cys), and p.(Arg595Trp) where the sub-
jects who carry them had a milder phenotype (LDL-C, 
300–400 mg/dL). This could have been explained by 
the fact that the variant presented was benign and a 
heterozygous pathogenic variant was missed or the 
variant retained a fairly high LDL receptor activity (60-
80%) as happens for example with recycling variants.29 
Indeed this might help explain many cases of genetically 
defined HoFH individuals who presented LDL-C levels 
below the thresholds accepted by scientific societies to 
define HoFH as previously described for either adults 
and children.8,26 Functional studies are even more crucial 
in these cases to attribute a correct and definite diag-
nosis for each patient. This might have implications for 
patient management and also for genetic counseling 
and cascade screening.
Independent of its cause, the HoFH phenotype is 
associated with a stern prognosis when MACE are con-
cerned.30 In this population, an elevated frequency of 
either CHD or aortic/supra-aortic valve events of early-
onset were encountered in adults and especially children. 
One concerning finding is that most individuals were not 
adequately treated and that there was an elevated num-
ber of individuals not receiving lipid-lowering therapies. 
This study was not designed to identify the causes of 
these discrepancies, but lack of availably of more effec-
tive therapies like PCSK9 inhibitors, lomitapide, and 
LDL-apheresis in countries outside Europe might have 
influenced on the findings. Indeed, recent evidence 
shows the influence of socioeconomic development on 
adequacy of care and availability of lipid-lowering medi-
cations for FH individuals in developed and developing 
nations.31 At any rate, results presented here are impor-
tant to show the inadequate situation and severity of 
disease in the region, and these data should be taken 
to governments to improve models of care, especially 
availability of LDL-apheresis4 that is the gold standard 
for treatment of these individuals.
This study has several limitations: (1) its retrospective 
design and absence of some clinical information reduces 
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the accuracy of the findings, however, this was the case 
with many other descriptions of HoFH populations8–10; 
(2) despite the elevated number of cases included in 
the study, this may represent only 1/5 of the at least 
predicted 680 homozygotes in the region; (3) the lack 
of a common evaluation and treatment protocol for the 
different centers from the different countries involved 
may explain heterogeneity of some findings; (4) a com-
plete lipid profile and Lp(a) values were not available in 
all cases; and finally (5) the highest reported lipid val-
ues were not necessary untreated. However, there are 
some strengths including the elevated number of sub-
jects, especially children in comparison with previous 
observations,26 the high rate of genetic diagnosis and 
careful molecular characterization of studied subjects, 
and information on homozygous FH coming especially 
from Latin America countries, where FH is severely 
underdiagnosed.14
In conclusion, HoFH in Iberoamerica is character-
ized by a high frequency of early-onset cardiovascular 
disease, even in children. Phenotype and cardiovascular 
complications are heterogeneous and associated with 
the type of molecular defect. Finally, LDL-C levels in 
HoFH are highly uncontrolled.
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